Kosan Biosciences to Present at the Leerink Swann Solid Tumors Roundtable Conference
06 Mayo 2008 - 3:00PM
PR Newswire (US)
HAYWARD, Calif., May 6 /PRNewswire-FirstCall/ -- Kosan Biosciences
Incorporated (NASDAQ:KOSN) announced today that Jane Green, Kosan's
Vice President, Corporate Communications, will present at the
Leerink Swann Solid Tumors Roundtable Conference in New York at the
Grand Hyatt Hotel on Friday, May 9, 2008 at 11:10 a.m. EDT. A live
webcast of the presentation can be accessed through
http://www.wsw.com/webcast/leerink15/kosn/. Interested parties may
also access a live webcast of the presentation by visiting the
"Events Calendar" page under the "Investors/Press" tab on Kosan's
website at http://www.kosan.com/. A recorded replay of the
presentations will be available for two weeks. About Kosan Kosan
Biosciences is a biotechnology company advancing two new classes of
anticancer agents through clinical development -- a Hsp90 (heat
shock protein 90) inhibitor and an epothilone. Hsp90 inhibitors
have a novel mechanism of action targeting multiple pathways
involved in cancer cell growth and survival. Tanespimycin (KOS-953)
is being tested in combination with Velcade(R) (bortezomib) in
patients with multiple myeloma in a clinical program called TIME.
Tanespimycin is also being studied in HER2-positive metastatic
breast cancer in combination with Herceptin(R) (trastuzumab).
Epothilones inhibit cell division with a mechanism of action
similar to taxanes, one of the most successful classes of
anti-tumor agents. KOS-1584 is in a Phase 2 clinical trial in
patients with non-small cell lung cancer. Kosan's motilin agonist
compound, KOS-2187, licensed to Pfizer for development in
gastroesophagel reflux disease, is in a Phase 1 trial. For
additional information on Kosan Biosciences, please visit the
company's website at http://www.kosan.com/. Velcade(R) (bortezomib)
is a registered trademark of Millennium Pharmaceuticals, Inc.
Herceptin(R) (trastuzumab) is a registered trademark of Genentech,
Inc. DATASOURCE: Kosan Biosciences Incorporated CONTACT: Jane
Green, VP, Corporate Communications of Kosan Biosciences
Incorporated, +1-510-731-5335, or mobile, +1-415-652-4819, Web
site: http://www.kosan.com/
Copyright
Kosan Biosciences (MM) (NASDAQ:KOSN)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Kosan Biosciences (MM) (NASDAQ:KOSN)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024
Real-Time news about Kosan Biosciences (MM) (NASDAQ): 0 recent articles
Más de Kosan Biosciences Incorporated (MM) Artículos de Noticias